BIOMAT Database Logo BIOMAT Database Logo

Vindesine in the treatment of small cell and non-small cell bronchogenic carcinoma: preliminary results. 1980

K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014747 Vinblastine Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) Vincaleukoblastine,Cellblastin,Lemblastine,Velban,Velbe,Vinblastin Hexal,Vinblastina Lilly,Vinblastine Sulfate,Vinblastinsulfat-Gry,Sulfate, Vinblastine
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine
D014751 Vindesine Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS). Compound 112531,Desacetylvinblastine Amide,Eldisine,Enison,NSC-245467,Vindesin,Vindesine Sulfate,NSC 245467,NSC245467,Sulfate, Vindesine

Related Publications

K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.
January 1981, Cancer treatment reports,
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
Cis-platin, vindesine, doxorubicin and cyclophosphamide in the treatment of non-small cell bronchogenic carcinoma.
July 1989, Journal of chemotherapy (Florence, Italy),
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
Phase II evaluation of vindesine in non-small cell bronchogenic carcinoma.
November 1983, Cancer treatment reports,
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
[Chemotherapy of advanced non-small cell bronchogenic carcinoma with cisplatin and vindesine].
August 1984, Onkologie,
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma.
December 1986, Cancer treatment reports,
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
[Results of combined treatment of small-cell bronchogenic carcinoma].
January 1980, Vnitrni lekarstvi,
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
Combination chemotherapy with vindesine and cisplatin for refractory small cell bronchogenic carcinoma.
June 1986, Cancer treatment reports,
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma.
February 1984, Cancer treatment reports,
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
[Chemotherapy of the non-small cell bronchogenic carcinoma].
February 1983, Onkologie,
K Mattson, and L R Holsti, and M Salmo, and M Saastamoinen, and S Ahlstedt, and P Holsti
Comparison of vincristine and vindesine in the treatment of inoperable non-small cell bronchial carcinoma.
December 1983, Cancer treatment reports,
Copied contents to your clipboard!